Your browser doesn't support javascript.
loading
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
Cruz-Teran, Carlos; Tiruthani, Karthik; McSweeney, Morgan; Ma, Alice; Pickles, Raymond; Lai, Samuel K.
Affiliation
  • Cruz-Teran C; Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Tiruthani K; Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • McSweeney M; Inhalon Biopharma, Durham, NC 27709, USA.
  • Ma A; UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Pickles R; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Lai SK; Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Inhalon Biopharma, Durham, NC 27709, USA; UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Adv Drug Deliv Rev ; 169: 100-117, 2021 02.
Article in En | MEDLINE | ID: mdl-33309815
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 4_TD Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Immunologic Factors / Antibodies, Monoclonal Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Adv Drug Deliv Rev Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 4_TD Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Immunologic Factors / Antibodies, Monoclonal Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Adv Drug Deliv Rev Year: 2021 Document type: Article